Home > Healthcare > Medical Services > Inpatient and Outpatient Services > Bile Duct Cancer Market
Bile Duct Cancer Market size was valued at USD 3.6 billion in 2023 and is expected to expand at a CAGR of 8.5% between 2024 and 2032. One of the major growth drivers is the increasing incidence of bile duct cancer globally, which has led to a greater demand for effective treatment options. Additionally, advancements in medical technology and increased awareness among healthcare professionals and patients have contributed to the market's growth.
Furthermore, the rise in research and development activities focusing on innovative therapies and targeted treatments for bile duct cancer has propelled market expansion. For instance, in 2021, the U.S. FDA granted accelerated approval to the targeted therapeutic infigratinib (Truseltiq) for certain adults with previously treated advanced cholangiocarcinoma. Thus, with ongoing efforts to improve early detection and development of more personalized treatment approaches.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Bile Duct Cancer Market Size in 2023: | USD 3.6 Billion |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 8.5% |
2032 Value Projection: | USD 7.4 Billion |
Historical Data for: | 2018 - 2023 |
No. of Pages: | 115 |
Tables, Charts & Figures: | 188 |
Segments covered: | Type, Treatment, Treatment Provider, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Bile duct cancer, also known as cholangiocarcinoma, is a rare but aggressive type of cancer that forms in the bile ducts, which are thin tubes that connect the liver and the gallbladder to the small intestine. Bile duct cancer can occur in any part of the bile duct system, including the intrahepatic (inside the liver) and extrahepatic (outside the liver) bile ducts.